

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/79153 A1(51) International Patent Classification⁷: C07C 229/64,
311/21, A61K 31/196

(21) International Application Number: PCT/KR00/00366

(22) International Filing Date: 19 April 2000 (19.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: NEUROTECH CO., LTD. [KR/KR]; 106, Industrial Academy, Ajou University, 29-9, Wonchun-dong, Paldal-ku, Suwon-si, Kyunggi-do 442-380 (KR).

(72) Inventors: GWAG, Byoung, Joo; 7-703, Kyungnam Apartment, 1028-1, Bangbae-3-dong, Seocho-ku, Seoul 137-063 (KR). LEE, Young, Ae; 77, Wonchun-dong, Paldal-ku, Suwon-si, Kyunggi-do 442-380 (KR). RYU, Bo, Rum; 101-54, Maetan-1-dong, Paldal-ku, Suwon-si,


Kyunggi-do 442-371 (KR). YOON, Sung, Hwa; 321-602, Samik Apartment, 957-6, Youngtong-dong, Paldal-ku, Swon-si, Kyunggi-do 442-470 (KR). MOON, Ho, Sang; 102-1207 Sunkyoung Apartment, 105 Wooman-dong, Paldal-ku, Suwon-si, Kyunggi-do 442-190 (KR).

(74) Agents: YOON, Dong-Yol et al.; Yeosam Building, 9th floor, 648-23, Yoksam-dong, Kangnam-ku, Seoul 135-748 (KR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent

[Continued on next page]

(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM



(57) Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn^{2+} , and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn^{2+} neurotoxicity, and free radical neurotoxicity.

WO 01/79153 A1



(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM

5

FIELD OF THE INVENTION

The present invention is related to novel salicylic compounds, compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death.

10

BACKGROUND OF THE INVENTION

<Excitotoxicity and Brain Diseases>

15

Excess activation of ionotropic glutamate receptors sensitive to N-methyl-D-aspartate (NMDA receptors) produces neuronal death and has been known to mediate various neurological diseases [Choi, *Neuron* 1:623-634 (1988)]. Glutamate, the excitatory neurotransmitter, is massively accumulated in brain subjected to hypoxic-ischemic injuries, which activates ionotropic glutamate receptors permeable to Ca^{2+} and Na^+ and then causes neuronal death [Choi and Rothman, *Annu Rev Neurosci* 13:171-182 (1990)]. Antagonists of NMDA receptors remarkably attenuate brain injury following hypoglycemia, hypoxia, or hypoxic-ischemia [Simon, Swan, Griffiths, and Meldrum, *Science* 226:850-852 (1984); Park, Nehls, Graham, Teasdale, and McCulloch, *Ann Neurol* 24:543-551 (1988); Wieloch, *Science* 230:681-683 (1985); Kass, Chambers, and Cottrell, *Exp. Neurol.* 103:116-122 (1989); Weiss, Goldberg, and Choi, *Brain Res.* 380:186-190 (1986)]. Thus, NMDA receptor antagonists possess therapeutic potentials to protect brain against hypoglycemia, hypoxia, and hypoxic-ischemic injuries.

25

Excitotoxicity appears to contribute to neuronal degeneration following traumatic brain injury (TBI). Levels of quinolinic acid, an endogenous agonist of NMDA receptors, was increased 5- to 50-fold in human patients with TBI [E. H. Sinz, P. M. Kochanek, M. P. Heyes, S. R. Wisniewski, M. J. Bell, R. S. Clark, S. T. DeKosky, A.

30

- R. Blight, and D. W. Marion]. Quinolinic acid is increased in the cerebrospinal fluid and associated with mortality after TBI in humans [*J.Cereb.Blood Flow Metab.* 18:610-615, (1998)]. In animal models of brain trauma, levels of glutamate and aspartate were markedly increased [Faden, Demediuk, Panter, and Vink, *Science* 244:798-800 (1989)]. Glutamate release was also observed in rat spinal cord following impact trauma [Demediuk, Daly, and Faden. *J Neurochem J. Neurochem.* 52 :1529-1536 (1989)]. NMDA receptor antagonists attenuate neuronal death following traumatic brain or spinal cord injuries [Faden, Lemke, Simon, and Noble. *J.Neurotrauma.* 5:33-45(1988); Okiyama, Smith, White, Richter, and McIntosh. *J.Neurotrauma.* 14:211-222 (1997)].
- 10 Glutamate plays a central role in the induction and the propagation of seizures [Dingledine, McBain, and McNamara, *Trends.Pharmacol.Sci.* 11:334-338 (1990); Holmes. *Cleve.Clin.J.Med.* 62:240-247 (1995)]. NMDA receptor antagonists were shown to act as anticonvulsants and antiepileptogenic drugs in various models of epilepsy [Anderson, Swartzwelder, and Wilson, *J.Neurophysiol.* 57:1-21 (1987);
- 15 Wong, Coulter, Choi, and Prince. *Neurosci.Lett.* 85:261-266 (1988); McNamara, Russell, Rigsbee, and Bonhaus, *Neuropharmacology* 27:563-568 (1988)].
- Amyotrophic lateral sclerosis (ALS) is accompanied by degeneration of both upper and lower motor neurons and marked by neurogenic atrophy, weakness, and fasciculation. While the pathogenesis of ALS remains to be resolved, excitotoxicity has
- 20 been expected to participate in the process of ALS. In particular, ALS patients show increased levels of extracellular glutamate and defects in glutamate transport. Administration of excitotoxins mimicked pathological changes in the spinal cord of ALS patients [Rothstein. *Clin.Neurosci.* 3:348-359 (1995); Ikonomidou, Qin, Labruyere, and Olney *J.Neuropathol.Exp.Neurol.* 55:211-224 (1996)].
- 25 Antagonizing NMDA receptors appears to be applied to treat Parkinson's disease (PD). Several antagonists of NMDA receptors protect dopaminergic neurons from the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [Lange, Loschmann, Sofic, Burg, Horowski, Kalveram, Wachtel, and Riederer. *Naunyn Schmiedebergs Arch.Pharmacol.* 348:586-592 (1993); Brouillet and Beal. *Neuroreport.*
- 30 4:387-390 (1993)]. NMDA receptor antagonists also ameliorate levodopa-induced dyskinesia and thus can improve the therapeutic effects of levodopa [Papa and Chase,

Ann.Neurol. 39:574-578 (1996); Marin, Papa, Engber, Bonastre, Tolosa, and Chase, *Brain Res.* 736:202-205 (1996)]. Two NMDA receptor antagonists, memantine and dextromethophan, have been proved beneficial in treating PD patients [Verhagen, Del Dotto, Natte, van den Munckhof, and Chase, *Neurology* 51:203-206 (1998); Merello, 5 Nouzeilles, Cammarota, and Leiguarda. *Clin.Neuropharmacol.* 22:273-276 (1999)].

Huntington's disease (HD) is a progressive neurodegenerative disease predominantly affecting small- and medium-sized interneurons but sparing NADPH-diaphorase neurons containing somatostatin and neuropeptide in the striata. These pathological features of HD are observed in the striatal tissues following the intrastriatal 10 injections of quinolinic acid or cultured striatal neurons exposed to NMDA, raising the possibility that NMDA receptor-mediated neurotoxicity contributes to selective neuronal death in HD [Koh, Peters, and Choi, *Science* 234:73-76 (1986); Beal, Kowall, Ellison, Mazurek, Swartz, and Martin, *Nature* 321:168-171 (1986); Beal, Ferrante, Swartz, and Kowall. *J.Neurosci.* 11:1649-1659 (1991)].

15

<Free radicals and Brain Diseases>

Free radicals are produced in degenerating brain areas following hypoxic-ischemia or traumatic brain and spinal cord injuries [Hall and Braughler, *Free Radic.Biol.Med.* 6:303-313 (1989); Anderson and Hall, *Ann.Emerg.Med.* 22:987-992 20 (1993); Siesjo and Siesjo, *Eur.J.Anaesthesiol.* 13:247-268(1996); Love, *Brain Pathol.* 9:119-131 (1999)]. Antioxidants or maneuvers scavenging free radicals attenuate brain damages by hypoxic-ischemia or traumatic injuries [Faden, *Pharmacol.Toxicol.* 78:12-17 (1996); Zeidman, Ling, Ducker, and Ellenbogen, *J.Spinal.Disord.* 9:367-380 (1996); Chan, *Stroke* 27:1124-1129 (1996); Hall, *Neurosurg.Clin.N.Am.* 8:195-206 25 (1997)]. Extensive evidence supports that free radicals can be produced in brain areas undergoing degeneration in neurodegenerative diseases possibly due to point mutations in Cu/Zn superoxide dismutase in ALS, decreased glutathione and increased iron in PD, accumulation of iron in AD, or mitochondrial dysfunction in HD [Rosen, Siddique, Patterson, Figlewicz, Sapp, Hentati, Donaldson, Goto, O'Regan, and Deng. *Nature* 30 362:59-62 (1993); Jenner and Olanow, *Neurology* 47:S161-S170 (1996); Smith, Harris, Sayre, and Perry, *Proc.Natl.Acad.Sci.U.S.A.* 94:9866-9868 (1997); Browne, Ferrante,

and Beal, *Brain Pathol.* 9:147-163 (1999)]. Accordingly, antioxidants have been neuroprotective against such neurodegenerative diseases [Jenner, *Pathol. Biol.(Paris.)* 44:57-64 (1996); Beal, *Ann. Neurol.* 38:357-366 (1995); Prasad, Cole, and Kumar. *J.Am.Coll.Nutr.* 18:413-423 (1999); Eisen and Weber, *Drugs Aging* 14:173-196 (1999); Grundman, *Am.J.Clin.Nutr.* 71:630S-636S (2000)].

<Zinc and Brain Diseases>


Zn^{2+} mediates neurodegenerative process observed in seizure, ischemia, trauma, and Alzheimers disease (AD). The central administration of kainate, a seizure-inducing excitotoxin, causes the translocation of Zn^{2+} into postsynaptic degenerating neurons in several forebrain areas [Frederickson, Hernandez, and McGinty. *Brain Res.* 480:317-321 (1989)]. Blockade of Zn^{2+} translocation with Ca-EDTA attenuates neuronal loss following a transient forebrain ischemia or traumatic brain injury [Koh, Suh, Gwag, He, Hsu and Choi, *Science* 272: 1013-1016 (1996); Suh, Chen, Motamedi, Bell, Listiak, Pons, Danscher, and Frederickson, *Brain Res.* 852 :268-273 (2000)]. Zn^{2+} is observed in the extracellular plaque and degenerating neurons in AD, which likely contributes to neuronal degeneration in AD [Bush, Pettingell, Multhaup, Paradis, Vonsattel, Gusella, Beyreuther, Masters, and Tanzi, *Science* 265:1464-1467 (1994); Suh, Jensen, Jensen, Silva, Kesslak, Danscher, and Frederickson. *Brain Res.* 852:274-278 852 (2000)].

20

SUMMARY OF THE INVENTION

The present invention provides novel 5-benzylamino salicylic acid (BAS) and its derivatives represented by the following formula (I) :

25



wherein,

X is CO, SO₂ or (CH₂)_n (where n is an integer of 1 to 5, inclusive);

R₁ is hydrogen, alkyl or alkanoyl;

R₂ is hydrogen or alkyl;

5 R₃ is hydrogen or an acetoxy group; and

R₄ is phenyl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, haloalkyl, and C₁- C₅ alkoxy; or a pharmaceutically-acceptable salt thereof.

10 The present invention also provides method for protecting central neurons from acute or chronic injuries to central nervous system (CNS), comprising administering to a patient or a mammal suffering from such CNS injuries a therapeutically appropriate amount of a neuroprotective compound represented by Formula (I).

15 The present invention still provides a composition for protecting central neurons from acute or chronic injuries to central nervous system comprising a neuroprotective compound represented by Formula (I) in a therapeutically appropriate amount.

20 The present invention still provides a method for treating or preventing neurological diseases linked to NMDA neurotoxicity, Zn²⁺ neurotoxicity or oxidative stress, comprising administering to a patient or a mammal suffering from such diseases a therapeutically effective amount of the compound represented by Formula (I).

25 The present invention more provides a use of the compound of Formula (I) in the manufacture of medicaments for protecting central neurons from acute or chronic injuries to central nervous system (CNS).

30 The above and other features of the present invention will be apparent to those of ordinary skill in the art from the detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (1a), continuously to 50 μ M Fe^{2+} (1b), or 300 μ M Zn^{2+} for 30 min (1c), alone or with inclusion of 10 - 300 μ M 5-amino salicylic acid (AS). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the bathing medium, mean \pm SEM (n = 9 - 12 (1a), n = 4 - 8 (1b) or n = 4 (1c) culture wells per condition), scaled to mean LDH efflux value 24 hr after sham wash (=0) and continuous exposure to 500 μ M NMDA (=100). * indicates significant difference from relevant control at $p < 0.05$ using ANOVA and Student-Neuman-Keuls' test.

Fig. 2. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (2a), continuously to 50 μ M Fe^{2+} (2b) or 10 mM BSO (2c), or 300 μ M Zn^{2+} for 30 min (2d), alone or with inclusion of indicated doses of 5-benzylamino salicylate (BAS). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 7 - 8 (2a), n = 3 - 6 (2b), n = 4 (2c), or n = 4 (2d) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

Fig. 3. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (3a), continuously to 50 μ M Fe^{2+} (3b), or 300 μ M Zn^{2+} for 30 min (3c), alone or with inclusion of indicated doses of 5-(4-nitrobenzyl)aminosalicylic acid (NBAS). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 7 - 8 (3a), n = 3 - 6 (3b), or n = 4 (3c) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

Fig. 4. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (4a), continuously to 50 μ M Fe^{2+} (4b), or 300 μ M Zn^{2+} for 30 min (4c), alone or with inclusion of indicated doses of 5-(4-chlorobenzyl)aminosalicylic acid (CBAS). Neuronal death was analyzed 24 hr later by measuring levels of LDH released

into the medium, mean \pm SEM (n = 3 - 4 (4a), n = 3 - 12 (4b), or n = 4 (4c) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

5 *Fig. 5.* Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (5a), continuously to 50 μ M Fe^{2+} (5b), or 300 μ M Zn^{2+} for 30 min (5c), alone or with inclusion of indicated doses of 5-(4-Trifluoromethylbenzyl)aminosalicylic acid (TBAS). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 3 - 4
10 (5a), n = 3 - 11 (5b), or n = 4 (5c) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

Fig. 6. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M
15 NMDA for 10 min (6a) or continuously to 50 μ M Fe^{2+} (6b) alone or with inclusion of indicated doses of 5-(4-Fluorobenzyl)aminosalicylic acid (FBAS). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 7 - 8 (6a) or n = 4 - 8 (6b) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-
20 Neuman-Keuls test.

Fig. 7. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (7a) or continuously to 50 μ M Fe^{2+} (7b) alone or with inclusion of indicated doses of 5-(4-methoxybenzyl)aminosalicylic acid (MBAS). Neuronal death
25 was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 7 - 8 (7a) or n = 4 - 8 (7b) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

30 *Fig. 8.* Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (8a), continuously to 50 μ M Fe^{2+} (8b) or 10 mM BSO (8c), or 300

$\mu\text{M Zn}^{2+}$ for 30 min (8d), alone or with inclusion of indicated doses of 5-(pentafluorobenzyl)amino salicylic acid (PBAS). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 11 - 16 (8a), n = 3 - 6 (8b), n = 4 - 11 (8c), or n = 12 (8d) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

Fig. 9. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μM NMDA for 10 min (9a) or continuously to 50 $\mu\text{M Fe}^{2+}$ (9b), alone or with inclusion of indicated doses of ethyl-5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate (NAHE). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 10 - 12 (9a) or n = 3 - 4 (9b) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

15

Fig. 10. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μM NMDA for 10 min (10a) or continuously to 50 $\mu\text{M Fe}^{2+}$ (10b) alone or with inclusion of indicated doses of 5-(4-nitrobenzyl)-N-acetylamino-2-hydroxy ethylbenzoate (NNAHE). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 3 - 4 (10a) or n = 3 - 4 (10b) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

20

Fig. 11. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μM NMDA for 10 min (11a) or continuously to 50 $\mu\text{M Fe}^{2+}$ (11b), alone or with inclusion of indicated doses of 5-(4-nitrobenzyl)-N-acetylamino-2-acetoxy ethylbenzoate (NNAAE). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 10 - 12 (11a), n = 7 - 8 (11b), or n = 4 (11c) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

30

Fig. 12. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (12a) or continuously to 50 μ M Fe^{2+} (12b), alone or with inclusion of indicated doses of 5-(4-nitrobenzoyl)aminosalicylic acid(NBAA). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 7 - 8 (12a) or n = 3 - 4 (12b) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

Fig. 13. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (13a) or continuously to 50 μ M Fe^{2+} (13b) alone or with inclusion of indicated doses of 5-(4-nitrobenzenesulfonyl)aminosalicylic acid(NBSAA). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 3 - 4 (13a) or n = 2 - 8 (13b) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

Fig. 14. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (14a) or continuously to 50 μ M Fe^{2+} (14b), alone or with inclusion of indicated doses of 5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid(NPAA). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 4 (14a) or n = 4 - 8 (14b) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.

Fig. 15. Mouse cortical cell cultures (DIV 12 - 14) were exposed to 300 μ M NMDA for 10 min (15a) or continuously to 50 μ M Fe^{2+} (15b), alone or with inclusion of indicated doses of 5-[3-(4-nitrophenyl)-n-propyl]aminosalicylic acid (NPPAA). Neuronal death was analyzed 24 hr later by measuring levels of LDH released into the medium, mean \pm SEM (n = 4 (15a) or n = 3 - 8 (15b) culture wells per condition). * indicates significant difference from relevant control, at $p < 0.05$ using ANOVA and Student-Neuman-Keuls test.


DETAILED DESCRIPTION OF THE INVENTION

We have synthesized 5-benzylamino salicylic acid (BAS) and its derivatives
 5 and demonstrated that these synthetic compounds have multiple neuroprotective action.
 First, BAS and its derivatives attenuate NMDA neurotoxicity at doses of 100 - 1,000
 uM. Second, BAS and its derivatives are antioxidants and block free radical
 neurotoxicity at doses of 1 - 300 uM. Finally, BAS and its derivatives attenuate Zn^{2+}
 neurotoxicity. These novel and multiple neuroprotective effects of BAS and its
 10 derivatives are merited to treat stroke, traumatic brain and spinal cord injury, epilepsy,
 and neurodegenerative diseases that are accompanied by excitotoxicity, Zn^{2+}
 neurotoxicity, and free radical neurotoxicity.

The BAS and its derivatives may be synthesized from 5-aminosalicylic acid by
 15 reacting it with an appropriate compound. The following reaction schemes illustrate
 the synthesis of BAS and its derivatives.

Reaction Scheme 1

20



Reagents (a) : Benzyl bromide, 4-nitrobenzyl bromide, 4-chlorobenzyl chloride, 4-(trifluoro methyl)benzyl chloride, 4-fluorobenzyl bromide, 4-methoxybenzyl chloride, N,N-dimethyl foramide (DMF), triethylamine, room temperature, 4 hr.


25

A preferred class of compounds within Formula (I) comprises those compounds wherein X is CO, SO₂ or (CH₂)_n (where n is an integer of 1 - 5, inclusive); R₁ is

hydrogen, C₁- C₅ alkyl or C₂ - C₅ alkanoyl¹¹; R₂ is hydrogen or C₁- C₅ alkyl; R₃ is hydrogen or an acetoxy group; and R₄ is phenyl group which is unsubstituted or substituted with one or more selected from the group consisting of nitro, halogen, haloalkyl, and C₁- C₅ alkoxy; or a pharmaceutically-acceptable salt thereof.


5

Reaction Scheme 2.



Reagents (a) : N,N-dimethylformamide (DMF), triethylamine, room temperature, 4hr.

10 Reaction Scheme 3.




Reagents (a) EtOH, H₂SO₄, reflux, 6hr.

(b) Acetic anhydride, MeOH, 0°C, 30 min.

(c) Acetic anhydride, H₂SO₄, 0°C, 30 min.

A more preferred class of compounds within Formula (I) encompasses those
5 compounds wherein X is CO, SO₂ or (CH₂)_n (where n = 1,2,3); R₁ is hydrogen, C₁- C₃
alkyl or C₂ - C₃ alkanoyl; R₂ is hydrogen or C₁- C₃ alkyl; R₃ is hydrogen or an acetoxy
group; R₄ is phenyl group which is unsubstituted or substituted with one or more
selected from the group consisting of nitro, halogen, halo(C₁- C₃)alkyl and C₁- C₃
alkoxy; or a pharmaceutically- acceptable salt thereof.

Example 5.



Reagents (a) N,N-dimethylformamide (DMF), triethylamine, room temperature, 4hr.

5 Specific compounds of interest within Formula (I) are as follows:

5-benzylaminosalicylic acid (BAS),

5-(4-nitrobenzyl)aminosalicylic acid (NBAS),

(5-(4-chlorobenzyl)aminosalicylic acid (CBAS),

(5-(4-trifluoromethylbenzyl)aminosalicylic acid (TBAS),

10 (5-(4-fluorobenzyl)aminosalicylic acid (FBAS),

5-(4-methoxybenzyl)aminosalicylic acid (MBAS)
5-(pentafluorobenzyl)aminosalicylic acid (PBAS),
5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate(NAHE),
5-(4-nitrobenzyl)-*N*-acetylamino-2-hydroxy ethylbenzoate(NNAHE),
5 5-(4-nitrobenzyl)-*N*-acetylamino-2-acetoxy ethylbenzoate(NNAAE),
5-(4-nitrobenzoyl)aminosalicylic acid(NBAA),
5-(4-nitrobenzenesulfonyl)aminosalicylic acid(NBSAA),
5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid(NPAA), and
5-[3-(4-nitrophenyl)-*n*-propyl]aminosalicylic acid(NPPAA), or a pharmaceutically-
10 acceptable salt thereof.

The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable, and acids or
15 bases which may be employed to form such salts are, of course, well known to those skilled in the art. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid and such organic acids as maleic acid, succinic acid and citric acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium,
20 potassium, calcium and magnesium, or with organic bases, such as dicyclohexylamine. All of these salts may be prepared by conventional means from the corresponding compound of Formula (I) by reacting, for example, the appropriate acid or base with the compound of Formula (I).

25

The Synthesis Examples show the exemplary method for the preparation of the representative compounds (I).

Synthesis Example 1: Preparation of 5-benzylaminosalicylic acid (BAS)

30

To a solution of 5-aminosalicylic acid (2.0 g, 13 mmole, purchased from

Aldrich Chemical Company, USA) and triethylamine in dried DMF (25 ml) was added benzyl bromide (2.68 g, 1.90 ml, 15.6 mmole) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred for 4 hr at room temperature. Ice chip was added to the reaction mixture and then solvent was removed in *vacuo*. The reaction mixture was diluted with water and then extracted with ethyl acetate. The organic layer was washed with water and brine, and then dried over anhydrous MgSO_4 . After evaporation of the solvent, the residue was purified by column chromatography and recrystallized from methanol/ethyl acetate/hexane (1:3:1) to give 3.6 g (73% yield) of 5-benzylaminosalicylic acid as a white solid. : mp 173.5-174.5 °C (decompose).

Elemental analysis for $\text{C}_{14}\text{H}_{13}\text{NO}_3$.

	% C	% H	% N
Calculated	69.12	5.39	5.76
Found	69.30	5.18	5.63

Synthesis Example 2 : Preparation of 5-(4-nitrobenzyl)aminosalicylic acid (NBAS)

By following the similar procedure in Synthesis Example 1 by using 5-aminosalicylic acid (2.00 g, 13.0 mmole) and 4-nitrobenzyl bromide (3.38 g, 15.6 mmole), 2.90 g (79% yield) of 5-(4-nitrobenzyl)aminosalicylic acid was obtained as a pale yellow solid. : mp 211-212 °C.

Elemental analysis for $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}_5$.

	% C	% H	% N
Calculated	58.33	4.20	9.72
Found	58.38	4.21	9.71

Synthesis Example 3 : Preparation of 5-(4-chlorobenzyl)aminosalicylic acid (CBAS)

By following the similar procedure in Synthesis Example 1 by using 5-

aminosalicylic acid (500 mg, 3.26 mmole) and 4-chlorobenzyl chloride (630 mg, 3.91 mmole), 480 mg (53% yield) of 5-(4-chlorobenzyl)aminosalicylic acid was obtained as a white solid. : mp 227-228 °C.

5 Elemental analysis for $C_{14}H_{12}ClNO_3$.

	% C	% H	% N
Calculated	60.55	4.36	5.04
Found	60.43	4.21	5.02

Synthesis Example 4 : Preparation of 5-(4-trifluoromethylbenzyl)aminosalicylic acid (TBAS)

10

By following the similar procedure in Synthesis Example 1 by using 5-aminosalicylic acid (500 mg, 3.26 mmole) and 4-(trifluoromethyl)benzyl chloride (760 mg, 3.92 mmole), 510 mg (50% yield) of 5-(4-(trifluoromethyl)benzyl)aminosalicylic acid was obtained as a white solid. : mp > 188 °C (decompose).

15

Elemental analysis for $C_{14}H_{12}F_3NO_3$.

	% C	% H	% N
Calculated	57.88	3.89	4.50
Found	57.61	3.98	4.44

Synthesis Example 5 : Preparation of 5-(4-fluorobenzyl)aminosalicylic acid (FBAS)

20

By following the similar procedure in Synthesis Example 1 by using 5-aminosalicylic acid (500 mg, 3.26 mmole) and 4-fluorobenzyl bromide (740 mg, 3.92 mmole), 480 mg (44% yield) of 5-(4-fluorobenzyl)aminosalicylic acid was obtained as a white solid. : mp > 210 °C (decompose).

25

Elemental analysis for $C_{14}H_{12}FNO_3$.

	% C	% H	% N
Calculated	64.36	4.63	5.36
Found	64.10	4.42	5.07

Synthesis Example 6 : Preparation of 5-(4-methoxybenzyl)aminosalicylic acid (MBAS)

- 5 By following the similar procedure in Synthesis Example 1 by using 5-aminosalicylic acid (1.00 g, 6.53 mmole) and 4-methoxybenzyl chloride (1.23 g, 7.84 mmole), 890 mg (50% yield) of 5-(4-methoxybenzyl)aminosalicylic acid was obtained as a white solid. : mp 205-206 °C.

- 10 Elemental analysis for $C_{15}H_{15}NO_4$.

	% C	% H	% N
Calculated	65.92	5.53	5.13
Found	65.83	5.45	5.07

Synthesis Example 7: Preparation of 5-(pentafluorobenzyl)aminosalicylic acid

- 15 By following the similar procedure in Synthesis Example 1 by using 5-aminosalicylic acid (500 mg, 3.26 mmole) and pentafluorobenzyl bromide (1.02 g, 3.92 mmole), 650 mg (60% yield) of 5-(pentafluorobenzyl)aminosalicylic acid was obtained as a white solid. : mp >190 °C (decompose).

- 20 Elemental analysis for $C_{14}H_8F_5NO_3$.

	% C	% H	% N
Calculated	50.46	2.42	4.20
Found	50.53	2.19	4.23

Synthesis Example 8: Preparation of 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate

To a solution of 5-(4-nitrobenzyl)aminosalicylic acid (1.0 g, 3.4 mmole) in ethanol (35 ml) was carefully added Conc.H₂SO₄ (3.5 ml) at 0 °C. The reaction mixture was stirred for 6 hr at 80 °C and cooled to room temperature. After the solvent was removed in *vacuo*, the reaction mixture was extracted with ethyl acetate. The organic layer was washed with H₂O, 10% NaHCO₃ solution, 5% HCl solution and brine. After the organic layer was dried over anhydrous MgSO₄, it was concentrated in *vacuo*. The residue was purified by column chromatography and recrystallized from ethyl acetate/hexane (1:2) to give 500 mg (46% yield) of 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate as a yellow solid. : mp 106.5-107.5 °C.

Elemental analysis for C₁₆H₁₆N₂O₅.

	% C	% H	% N
Calculated	60.75	5.10	8.86
Found	60.68	5.24	9.04

15 Synthesis Example 9 :Preparation of 5-(4-nitrobenzyl)-*N*-acetylamino-2-hydroxy ethylbenzoate

To a solution of 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate (500 mg, 1.58 mmole) in dried methanol (50 ml) was carefully added acetic anhydride (5 ml) at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred for 2 hr at 10 °C. After ice chip was slowly added to the reaction mixture, the solvent was removed in *vacuo*. The reaction mixture was extracted with ethyl acetate and H₂O, and the organic layer was washed with H₂O, 10% NaHCO₃ (30 ml x 3) solution, 5% HCl (30 ml x 2) solution and brine. The organic solution was dried over anhydrous MgSO₄ and evaporated. The residue was purified by column chromatography and recrystallized from ethyl acetate/hexane (1:3) to give 400 mg (70 % yield) of 5-(4-nitrobenzyl)-*N*-acetylamino-2-hydroxy ethylbenzoate as a pale yellow solid. : mp 105.5-106.0 °C.

Elemental analysis for C₁₈H₁₈N₂O₆.

	% C	% H	% N
Calculated	60.33	5.06	7.82
Found	60.54	5.35	8.12

Synthesis Example 10 : Preparation of 5-(4-Nitrobenzyl)-*N*-acetylamino-2-acetoxy ethylbenzoate

5

To a solution of 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate (500 mg, 1.58 mmole) in acetic anhydride (10 ml) was carefully added conc.H₂SO₄ (0.5 ml) at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred for 30 min at 10 °C. After ice chip was slowly added to the reaction mixture, the solvent was removed in *vacuo*. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed H₂O, 10% NaHCO₃ (30ml x 3) solution, 5% HCl (30ml x 2) solution and brine and then dried over anhydrous MgSO₄. After evaporation of the solvent, the residue was purified by column chromatography to give 450 mg (71% yield) of 5-(4-nitrobenzyl)-*N*-acetylamino-2-acetoxy ethylbenzoate as pale yellow oil.

15

Elemental analysis for C₂₀H₂₀N₂O₇.

	% C	% H	% N
Calculated	60.00	5.03	7.00
Found	59.96	4.84	7.15

Synthesis Example 11: Preparation of 5-(4-nitrobenzoyl)aminosalicylic acid

20

By following the similar procedure in Synthesis Example 1 by using 5-aminosalicylic acid (500 mg, 3.26 mmole) and 4-nitrobenzoyl chloride (700 mg, 3.77 mmole), 550 mg (56% yield) of 5-(4-nitrobenzoyl)aminosalicylic acid was obtained as a pale yellow solid. : mp 270-271 °C.

25

Elemental analysis for C₁₄H₁₀N₂O₆.

	% C	% H	% N
Calculated	55.63	3.33	9.27
Found	55.82	3.43	9.08

Synthesis Example 12 : Preparation of 5-(4-nitrobenzenesulfonyl)aminosalicylic acid

- 5 By following the similar procedure in Synthesis Example 1 by using 5-aminosalicylic acid (500 mg, 3.26 mmole) and 4-nitrobenzenesulfonyl chloride (720 mg, 3.26 mmole), 390 mg (35% yield) of 5-(4-nitrobenzenesulfonyl)aminosalicylic acid was obtained as a yellow solid. : mp 239-240 °C.

- 10 Elemental analysis for $C_{13}H_{10}N_2O_7S$.

	% C	% H	% N	%S
Calculated	46.15	2.98	8.28	9.48
Found	46.27	2.92	8.34	9.51

Synthesis Example 13 : Preparation of 5-[2-(4-nitrophenyl)ethyl]aminosalicylic acid

- 15 By following the similar procedure in Synthesis Example 1 by using 5-aminosalicylic acid (500 mg, 3.26 mmole) and 4-nitrophenethyl bromide (900 mg, 3.92 mmole), 890 mg (50% yield) of 5-(4-nitrophenethyl)aminosalicylic acid was obtained as a pale yellow solid. : mp 234-236 °C.

- 20 Elemental analysis for $C_{15}H_{14}N_2O_5$.

	% C	% H	% N
Calculated	59.60	4.67	9.27
Found	59.77	4.79	9.24

Synthesis Example 14 : Preparation of 5-[3-(4-nitrophenyl)-n-propyl]aminosalicylic acid

By following the similar procedure in Synthesis Exmample 1 by using 5-aminosalicylic acid (500 mg, 3.26 mmole) and 3-(4-nitrophenyl)propyl bromide (950 mg, 3.92 mmole), 520 mg (50% yield) of 5-[3-(4-nitrophenyl)-n-propyl]aminosalicylic acid was obtained as a pale yellow solid. : mp 229-231 °C.

Elemental analysis for $C_{16}H_{16}N_2O_5$.

10

	% C	% H	% N
Calculated	60.75	5.10	8.86
Found	60.77	5.07	8.89

EXPERIMENTAL EXAMPLE

Primary cortical cell cultures from embryonic mice were prepared and used to examine neuroprotective action of compounds. Mouse cortical cell culture system has been extensively used to study mechanisms and pharmacological intervention of neuronal death in neurological diseases. In brief, mouse cerebral cortices were removed from brains of the 15 day-old-fetal mice, in accordance with a protocol approved by our institutional animal care committee. The neocortices were gently triturated and plated on 24 well plates (5 hemispheres/plate) precoated with 100 μ g/ml poly-D-lysine and 4 μ g/ml laminine. Plating media consist of Eagles minimal essential media (MEM, Earles salts, supplied glutamine-free) supplemented with 5% horse serum, 5% fetal bovine serum, 2 mM glutamine, and 21 mM glucose. Cultures were maintained at 37°C in a humidified 5% CO₂ atmosphere. After 7 days in vitro (DIV 7), cultures were shifted into a growth medium identical to the plating medium but lacking fetal serum. At DIV 7 - 9, 10 mM cytosine arabinofuranoside was included to halt overgrowth of glia. Mixed cultures of neurons and glia were then fed twice a week.

To induce neuronal injury by NMDA or Zn^{2+} , cortical cell cultures were exposed to toxic doses of NMDA for 10 min or Zn^{2+} for 30 min in a HEPES-buffered control salt solution (HCSS) : (in mM) 120 NaCl, 5KCl, 1.6 MgCl_2 , 2.3 CaCl_2 , 15 glucose, 20 HEPES and 10 NaOH. After exposure, cultures were washed out 3 times
5 and exchanged with MEM adjusted to 25 mM glucose and 26.2 mM sodium bicarbonate, and placed in the CO_2 incubator for the next 20 - 24 hr. To induce free radical neurotoxicity, cortical cell cultures were continuously exposed to Fe^{2+} or BSO for 20 - 24 hr, in MEM adjusted to 25 mM glucose and 26.2 mM sodium bicarbonate.

10 Overall cell injury was assessed microscopically under phase-contrast optics or by measuring amount of lactate dehydrogenase (LDH) released into the bathing medium 24 hr after neurotoxic insults as previously described (Koh and Choi, J Neurosci Methods 20:83-90, 1987). The percent neuronal death was normalized to the mean LDH value released 24 hr after continuous exposure 500 μM NMDA (=100) or a sham control
15 (=0).

To examine anti-oxidant effect, DPPH (2,2-diphenyl-1-picryl-hydrazyl radical), a stable free radical, was dissolved in ethanol to make a 100 μM solution. A compound was reacted with DPPH or ethanol. After incubation for 30 min, relative
20 decrease in DPPH absorption at 517 nm was measured by a spectrophotometer.

Experimental Example 1 : Anti-oxidant action of 5 - amino salicylic acid

The neuroprotective action of 5-amino salicylic acid (AS) was examined in
25 primary cortical cell cultures. Inclusion of 10 - 300 μM AS did not attenuate neuronal death evolving 24 hr after 10 min-exposure to 300 μM NMDA (Fig.1a). Interestingly, addition of 10 - 100 μM AS dose-dependently prevented free radical neurotoxicity following 24 hr-exposure to Fe^{2+} (Fig. 1b). Neuronal death 24 hr after 30 min-exposure to 300 μM Zn^{2+} was not reduced by continuous inclusion of AS during and post Zn^{2+}
30 treatment (Fig. 1c). The neuroprotective action of AS against free radical neurotoxicity was attributable to direct anti-oxidant property of the compound as AS decreased levels

of DPPH, a stable free radical (Table 1). Compared to trolox, a membrane-permeable form of vitamin E, AS was a weak anti-oxidant.

Table 1. Anti-oxidant property of AS

	Reactants	Concentrations of Trolox or AS (μ M)					
		0	3	10	30	100	300
A_{517nm}	DPPH alone	1.2 ± 0.05					
	DPPH + Trolox		1.08 ± 0.1	$0.89 \pm 0.08^*$	$0.39 \pm 0.06^*$	$0.05 \pm 0.01^*$	
	DPPH + AS		-	1.03 ± 0.05	$0.9 \pm 0.06^*$	$0.45 \pm 0.07^*$	$0.16 \pm 0.00^*$

5

AS or trolox was reacted with 100 μ M DPPH dissolved in ethanol for 30 min. Anti-oxidant property was analyzed by measuring changes in the level of DPPH at 517nm, mean \pm SEM (n = 3 test tubes per condition), after subtracting background value resulting from ethanol alone. * indicates significant difference from DPPH alone at $P < 0.05$, using ANOVA and Student-Neuman-Keuls test.

10

AS can protect neurons from free radical injuries without beneficial effects against NMDA or Zn^{2+} neurotoxicity. However, AS is weaker than trolox in scavenging free radicals.

15

Experimental Example 2 : Neuroprotective effects of 5-benzylaminosalicylic acid and its derivatives.

1. Neuroprotective effects of 5-benzylaminosalicylic acid

20

BAS was synthesized and examined against neuronal injuries induced in cortical cell cultures. Concurrent addition of 300 μ M 5-benzylaminosalicylic acid (BAS) reduced NMDA-induced neuronal death approximately by 50% (Fig. 2a). Neuronal death following exposure to 50 μ M Fe^{2+} (Fig. 2b) or 10 mM BSO (Fig. 2c) was substantially reduced in the presence of 1 μ M BAS and near completely blocked by addition of 3 μ M BAS. Administration of 30 - 300 μ M BAS dose-dependently

25

reduced neuronal death 24 hr following exposure to 300 μM Zn^{2+} for 30 min (Fig 2d). Like AS or trolox, BAS acted as a direct anti-oxidant (Table 2). The anti-oxidant property of BAS was observed at a dose as low as 1 μM .

5

Table 2. Anti-oxidant property of BAS

[BAS], μM	0	1	3	10	30	100	300
$A_{517\text{nm}}$	1.2 ± 0.05	1.07 ± 0.07	1.01 ± 0.07	$0.71 \pm 0.09^*$	$0.21 \pm 0.04^*$	$0.15 \pm 0.02^*$	$0.16 \pm 0.01^*$

BAS was reacted with 100 μM DPPH dissolved in ethanol for 30 min. Anti-oxidant property was analyzed by measuring changes in DPPH at 517nm, mean \pm SEM ($n = 3$ test tubes per condition), after subtracting background value resulting from ethanol alone. * indicates significant difference from DPPH alone ([BAS] = 0) at $P < 0.05$, using ANOVA and Student-Neuman-Keuls test.

10

2. BAS derivatives

BAS derivatives were synthesized by substituting -H at para position of benzylamino group with $-\text{NO}_2$ [5-(4-nitrobenzylamino)salicylic acid, NBAS], $-\text{Cl}$ [5-(4-chlorobenzylamino)salicylic acid, CBAS], $-\text{CF}_3$ [5-(4-trifluoromethylbenzylamino)salicylic acid, TBAS]. This substitution with electron-withdrawing group did not reduce neuroprotective effects of BAS against NMDA, Zn^{2+} , or free radical neurotoxicity (Figs. 3 - 5). These BAS derivatives were more potent than BAS in preventing free radical neurotoxicity.

20

Table 3. Anti-oxidant property of NBAS

[NBAS], μM	0	10	30	100	300
$A_{517\text{nm}}$	1.2 ± 0.01	$0.37 \pm 0.1^*$	$0.04 \pm 0.01^*$	$0.04 \pm 0.00^*$	$0.04 \pm 0.00^*$

NBAS was reacted with 100 μM DPPH dissolved in ethanol for 30 min. Anti-oxidant property was analyzed by measuring changes in DPPH at 517nm, mean \pm

25

ethanol alone. * indicates significant difference from DPPH alone ([PBAS] = 0) at $P < 0.05$, using ANOVA and Student-Neuman-Keuls test.

Experimental Example 4 : Neuroprotective effects of NBAS derivatives (X = CH₂)

5

Several derivatives of PBAS such as 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate (NAHE; R₁ = H, R₂ = CH₂CH₃, R₃ = H), 5-(4-nitrobenzyl)-N-acetylamino-2-hydroxy ethylbenzoate (NNAHE; R₁ = COCH₃, R₂ = CH₂CH₃, R₃ = H), and 5-(4-nitrobenzyl)-N-acetylamino-2-acetoxy ethylbenzoate (NNAAE; R₁ = COCH₃,
 10 R₂ = CH₂CH₃, R₃ = COCH₃) were synthesized and their neuroprotection action was examined in cortical cell cultures. These derivatives attenuated NMDA neurotoxicity at 300 μ M (Figs. 9 - 11). Inclusion of 10 μ M NAHE, NNAHE, or NNAAE blocked Fe²⁺-induced free radical neurotoxicity.

15 Experimental Example 5 : Neuroprotective effects of NBAS derivatives

(X = CO, SO₂, CH₂CH₂ or CH₂CH₂CH₂)

The group of X (CH₂) of NBAS was substituted with CO [5-(4-nitrobenzoyl) aminosalicilyc acid; NBAA], SO₂ [5-(4-nitrobenzenesulfonyl)aminosalicylic acid;
 20 NBSAA], CH₂CH₂ [5-(4-nitrophenethyl)aminosalicylic acid; NPAA], or CH₂CH₂CH₂ [5-[3-(4-nitrophenyl)-n-propyl]aminosalicylic acid; NPPAA]. NBAA at a dose of 30 μ M significantly attenuated NMDA neurotoxicity. However, its protective effect against NMDA was not further increased up to doses of 300 μ M (Fig. 12a). Interestingly, inclusion of 30 - 300 μ M NBSAA attenuated NMDA neurotoxicity in a
 25 dose-dependent manner (Fig. 13a). With inclusion of 300 μ M NBSAA, 90 - 100 % neuronal death following exposure to 300 μ M NMDA was markedly reduced. NBAA and NBSAA were still neuroprotective against Fe²⁺ injury but weaker than NBAS in reducing free radical neurotoxicity (Figs. 12 and 13; Table 5).

Substitution of CH₂ for X with CH₂CH₂ or CH₂CH₂CH₂ reduced protective potency of
 30 NBAS against NMDA neurotoxicity. Administration of 300 μ M NPAA or NPPAA slightly reduced NMDA-induced neuronal death in cortical neurons (Figs. 14 and 15).

In contrast, NPAA or NPPAA turned out to be more effective than NBAS in blocking free radical neurotoxicity as shown by complete blockade of Fe^{2+} -induced neuronal death in the presence of 1 μM NPAA or NPPAA.

5 Table 5. Anti-oxidant property of NBAS derivatives .

Reactants	DPPH alone	DPPH+NBAA	DPPH+NBSAA	DPPH+NPAA	DPPH+NPPAA
$A_{517\text{nm}}$	1.2 ± 0.01	$0.42 \pm 0.22^*$	$0.15 \pm 0.05^*$	$0.09 \pm 0.01^*$	$0.09 \pm 0.02^*$

NBAS derivatives (100 μM for each) were reacted with 100 μM DPPH dissolved in ethanol for 30 min. Anti-oxidant property was analyzed by measuring changes in DPPH at 517nm, mean \pm SEM (n = 3 test tubes per condition), after
 10 subtracting background value resulting from ethanol alone. * indicates significant difference from DPPH alone at $P < 0.05$, using ANOVA and Student-Neuman-Keuls test.

The above results show that the compounds of Formula (I) may be employed
 15 efficiently to prevent neurodegenerative diseases in association with excitotoxicity, Zn^{2+} neurotoxicity and free radical neurotoxicity.

Administration of compounds within Formula (I) to humans can be by any technique capable of introducing the compounds into the bloodstream of a human
 20 patient or mammals, including oral administration, and by intravenous, intramuscular and subcutaneous injections The mammals include, but not limited to, cats, dogs, poultry, cattle and the like.

Compounds indicated for prophylactic therapy will preferably be administered
 25 in a daily dose generally in a range from about 0.1 mg to about 20 mg per kilogram of body weight per day. A more preferred dosage will be a range from about 0.2 mg to about 10 mg per kilogram of body weight. Most preferred is a dosage in a range from about 0.5 to about 5 mg per kilogram of body weight per day. A suitable dose can be administered, in multiple sub-doses per day. These sub-doses may be administered in

unit dosage forms. Typically, a dose or sub-dose may contain from about 1 mg to about 100 mg of active compound per unit dosage form. A more preferred dosage will contain from about 2 mg to about 50 mg of active compound per unit dosage form. Most preferred is a dosage form containing from about 3 mg to about 25 mg of active
5 compound per unit dose.

The active compound is usually administered in a pharmaceutically-acceptable formulation. Such formulations may comprise the active compound together with one or more pharmaceutically-acceptable carriers or diluents. Other therapeutic agents may
10 also be present in the formulation. A pharmaceutically-acceptable carrier or diluent provides an appropriate vehicle for delivery of the active compound without introducing undesirable side effects. Delivery of the active compound in such formulations may be performed by various routes including oral, nasal, topical, buccal and sublingual, or by parenteral administration such as subcutaneous, intramuscular, intravenous and
15 intradermal routes.

Formulations for oral administration may be in the form of capsules containing the active compound dispersed in a binder such as gelatin or hydroxypropylmethyl cellulose, together with one or more of a lubricant, preservative, surface-active or
20 dispersing agent. Such capsules or tablets may contain controlled-release formulation as may be provided in a disposition of active compound in hydroxypropylmethyl cellulose.

Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and
25 suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.
30 Various equivalents, changes and modifications may be made without departing from the spirit and scope of this invention, and it is understood that such equivalent


embodiments are part of this invention.

REFERENCES

- A. I. Faden. *Pharmacol.Toxicol.* 78 (1):12-17, 1996.
- C. K. Joo, J. S. Choi, H. W. Ko, K. Park, S. Sohn, M. H. Chun, Y. J. Oh and B. J. Gwag.
 5 IOVS (16) 43:22, 1999.
- D. E. Bredesen, M. Wiedau-Pazos, J. J. Goto, S. Rabizadeh, J. A. Roe, E. B. Gralla, L. M. Ellerby, and J. S. Valentine. *Neurology* 47:S36-8, 1996.
- J.W. Olney. *Retina* 2:341-359, 1982.
- D. W. Choi and J. Y. Koh. *Annu.Rev.Neurosci.* 21:347-75:347-375, 1998.
- 10 D. W. Choi. *Neuron* 1:623-634, 1988.
- E. D. Hall, J. M. Braughler, and J. M. McCall. *J.Neurotrauma.* 5 (1):81-89, 1988.
- E. Y. Kim, J. Y. Koh, Y. H. Kim, S. Sohn and B. J. Gwag. *Eur. J Neurosci.* 11: 327-334.
 1999
- J. L. Montastruc, O. Rascol, and J. M. Senard. *Neurosci.Biobehav.Rev.* 21 (4):477-480,
 15 1997.
- K. A. Jellinger and C. Bancher. *J.Neural Transm.Suppl.* 54:77-95:77-95, 1998.
- M. F. Beal. *Ann.Neurol.* 38 (3):357-366, 1995.
- M. P. Cuajungco and G. J. Lees. *Brain Res.Rev.* 23 (3):219-236, 1997.
- P. H. Chan. *Stroke* 27 (6):1124-1129, 1996.
- 20 S. J. Won, E. C. Park, B. R. Ryu, H. W. Ko, S. Sohn, H. J. Kwon, and B. J. Gwag.
Neurobiology of Disease (in press), 2000

CLAIMS

1. A compound represented by the following formula (I) :



wherein,

X is CO, SO₂ or (CH₂)_n (where n is an integer of 1 to 5, inclusive);

R₁ is hydrogen, alkyl or alkanoyl;

10 R₂ is hydrogen or alkyl;

R₃ is hydrogen or an acetoxy group; and

R₄ is phenyl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, haloalkyl, and C₁- C₅ alkoxy; or a pharmaceutically-acceptable salt thereof.

15

2. A compound according to Claim 1, wherein X is CO, SO₂ or (CH₂)_n (where n is an integer of 1 – 5, inclusive); R₁ is hydrogen, C₁- C₅ alkyl or C₂ - C₅ alkanoyl; R₂ is hydrogen or C₁- C₅ alkyl; R₃ is hydrogen or an acetoxy group; and R₄ is phenyl group which is unsubstituted or substituted with one or more selected from the group consisting of nitro, halogen, haloalkyl, and C₁- C₅ alkoxy; or a pharmaceutically-acceptable salt thereof.

20

3. A compound according to Claim 1, wherein X is CO, SO₂ or (CH₂)_n (where n = 1,2,3); R₁ is hydrogen, C₁- C₃ alkyl or C₂ - C₃ alkanoyl; R₂ is hydrogen or C₁- C₃ alkyl; R₃ is hydrogen or an acetoxy group; R₄ is phenyl group which is unsubstituted or substituted with one or more selected from the group consisting of nitro, halogen, halo(C₁- C₃)alkyl and C₁- C₃ alkoxy; or a pharmaceutically- acceptable salt thereof.

25

4. A compound according to Claim 1, which is one selected from the group consisting of

- 5-benzylaminosalicylic acid (BAS),
5-(4-nitrobenzyl)aminosalicylic acid (NBAS),
5 (5-(4-chlorobenzyl)aminosalicylic acid (CBAS),
(5-(4-trifluoromethylbenzyl)aminosalicylic acid (TBAS),
(5-(4-fluorobenzyl)aminosalicylic acid (FBAS),
5-(4-methoxybenzyl)aminosalicylic acid (MBAS)
5-(4-pentafluorobenzyl)aminosalicylic acid (PBAS),
10 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate,
5-(4-nitrobenzyl)-*N*-acetylamino-2-hydroxy ethylbenzoate,
5-(4-nitrobenzyl)-*N*-acetylamino-2-acetoxy ethylbenzoate,
5-(4-nitrobenzoyl)aminosalicylic acid,
5-(4-nitrobenzenesulfonyl)aminosalicylic acid,
15 5-(4-nitrophenethyl)aminosalicylic acid, and
5-[3-(4-nitrophenyl)-*n*-propyl]aminosalicylic acid, or a pharmaceutically-acceptable salt thereof.

5. A use of the compound according to any one of Claim 1 to Claim 4 for
20 manufacture of medicaments for protecting central neurons from acute or chronic injuries to central nervous system(CNS).

6. A use according to Claim 5, wherein said CNS injuries result from ischemia, hypoxia, hypoglycemia, traumatic brain injury, traumatic spinal cord injury, epilepsy,
25 Huntington's disease, Parkinson's disease, Alzheimer's disease, or Amyotrophic lateral sclerosis.


7. A use according to Claim 5, wherein said CNS injuries are caused by activation of N-methyl-D-aspartate (NMDA) glutamate receptors, entry and accumulation of Zn^{2+} ,
30 or free radicals.

8.. A use according to any one Claim 5 to Claim 7, wherein said compound attenuates NMDA neurotoxicity, Zn^{2+} neurotoxicity, and blocks free radical neurotoxicity as a direct antioxidant.


5 9. A use of the compound according to any one of Claim 1 to Claim 4 for manufacture of medicaments for treating or preventing neurological diseases linked to NMDA neurotoxicity, Zn^{2+} neurotoxicity or oxidative stress.

10 10. A composition for protecting central neurons from acute or chronic injuries to central nervous system(CNS) comprising a neuroprotective compound according to any one of Claim 1 to Claim 4 in a therapeutically appropriate amount.


1/38

FIG. 1a


2/38

FIG. 1b


3/38

FIG. 1c


4/38

FIG. 2a


5/38

FIG. 2b


6/38

FIG. 2c


7/38

FIG. 2d


8/38

FIG. 3a


9/38

FIG. 3b


10/38

FIG. 3c


11/38

FIG. 4a


12/38

FIG. 4b


13/38

FIG. 4c


14/38

FIG. 5a


15/38

FIG. 5b


16/38

FIG. 5c


17/38

FIG. 6a


18/38

FIG. 6b


19/38

FIG. 7a


20/38

FIG. 7b


21/38

FIG. 8a


22/38

FIG. 8b


23/38

FIG. 8c


24/38

FIG. 8d


25/38

FIG. 9a


26/38

FIG. 9b


27/38

FIG. 10a


28/38

FIG. 10b


29/38

FIG. 11a


30/38

FIG. 11b


31/38

FIG. 12a


32/38

FIG. 12b


33/38

FIG. 13a


34/38

FIG. 13b


35/38

FIG. 14a


36/38

FIG. 14b

37/38

FIG. 15a

38/38

FIG. 15b

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 00/00366

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C07C 229/64; C07C 311/21; A61K 31/196

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C07C 229/64; C07C 311/21; A61K 31/196

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

QUESTEL: G-DARC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 2031227 (MERCK & CO) 7 January 1971 (07.01.71) <i>claims; examples.</i>	1-4
X	Nussbaumer, P. et al. Novel Antiproliferative Agents Derived from Lavendustin A. J. Med. Chem. 1994, 37(24), 4079-84 (Eng.). Columbus, Ohio, USA: Chemical abstracts, Vol.122, No. 1, 2 January 1995, page 1068, column 1, the abstract 9738a.	1-4
X	Mysyk D. D. et al. Chloromethylation of 4 - arenesulfonyl - N - methylamidoanisoles. Ukr. Khim. Zh. 33(2), 185-8(1967)(Russ.) Columbus, Ohio, USA: Chemical abstracts, Vol. 67, No. 5, 31 July 1967, page 2034, column 2, the abstract 21558m.	1-3
X	WO 86/03199 A1 (G.SPORTOLETTI) 5 June 2018 (05.06.18) 6 <i>table 1; claim 1.</i>	1-4

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

30 May 2001 (30.05.2001)

Date of mailing of the international search report

8 June 2001 (08.06.2001)

Name and mailing address of the ISA/AT

Austrian Patent Office

Kohlmarkt 8-10; A-1014 Vienna

Facsimile No. 1/53424/535

Authorized officer

HOFBAUER

Telephone No. 1/53424/225

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 00/00366

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0122827 A1 (CARPIBEM) 24 October 1984 (24.10.84) <i>claim 8.</i>	1-4
X	WO 94/13663 A1 (PFIZER INC.) 23 June 1994 (23.06.94) <i>page 60, lines 4-16.</i>	1-3
X	JP 54 125632 A (HISAMITSU SEIYAKU K.K.) Patent abstracts of Japan, Vol. 3, No. 147 (C-66) 5 December 1979 (05.12.79) (abstract).	1-3
X	JP 60 237041 A (YAMAMOTO KAGAYU KOGYO K.K.) Patent ab-stracts of Japan, Vol. 10, No. 107 (C-341) 22 April 1986 (22.04.86)	1-4
X	Rizzi E. et al. Electron impact mass spectrometry of some 5- amin-osalicylic acid derivatives. Rapid Commun. Mass Spectrom. 1994, 8(2), 158-62 (Eng.). Columbus, Ohio, USA: Chemical abstracts, Vol. 120, No. 15, 11 April 1994 (11.04.94) , page 972, column 1, the abstract 190897q.	1-4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 00/00366

The attention of the applicant is drawn to the fact that considering what is illustrated in the description the substituent "R32 in claim 1 should read as follows:

"R3 is hydrogen or an acetyl group;"

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 00/00366

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
DE	A	2031227	07-01-1971	CH A 536278	15-06-1973
				FR A5 2053015	16-04-1971
				GB A 1268465	29-03-1972
				JP B4 49020197	23-05-1974
				NL A 7008623	29-12-1970
				US A 3632760	04-01-1972
				US A 3674844	04-07-1972
EP	A1	122827	24-10-1984	AT E 20879	15-08-1986
EP	B1	122827	23-07-1986	AU A1 25537/84	20-09-1984
				AU B2 567332	19-11-1987
				CA A1 1218378	24-02-1987
				DE C0 3460323	28-08-1986
				DK A0 1174/84	27-02-1984
				DK A 1174/84	15-09-1984
				ES A1 530503	01-05-1985
				ES A5 530503	29-05-1985
				ES A1 8504681	16-07-1985
				FR A1 2542737	21-09-1984
				FR B1 2542737	02-01-1987
				GR A 81821	12-12-1984
				IE B 57094	22-04-1992
				JP A2 59176239	05-10-1984
				KR B1 9102945	11-05-1991
				PH A 19184	23-01-1986
				PT A 78238	01-04-1984
				PT B 78238	24-04-1986
				ZA A 8401808	27-02-1985
				FR A2 2555169	24-05-1985
				FR B2 2555169	10-04-1987
JP	A2	54125632	29-09-1979	JP B4 60056130	09-12-1985
JP	A2	60237041	25-11-1985	none	
MY	A	SYKD.D. E TAL. CHLO		none	
NU	A	SSBAUMER , P. ETAL		none	
RI	A	ZZIE. ETA L. ELECTR		none	
WO	A1	8603199	05-06-1986	AU A1 52311/86	18-06-1986
				CN A 85109554	23-07-1986
				DK A 3464/86	21-07-1986
				DK A0 3464/86	21-07-1986
				EP A1 236329	16-09-1987
				ES A1 549359	01-12-1986
				ES A5 549359	31-12-1986
				ES A1 8701717	01-03-1987
				GR A 852834	27-03-1986
				IT A0 8423799	29-11-1984
				IT A 1196348	16-11-1988
				JP T2 62501703	09-07-1987
				PT A 81566	01-12-1985
				PT B 81566	07-04-1987
				ZA A 8509035	27-08-1986
WO	A1	9413663	23-06-1994	AT E 194340	15-07-2000
				AU A1 51696/93	04-07-1994
				CA AA 2150123	23-06-1994
				CN A 1092771	28-09-1994
				DE C0 69328975	10-08-2000
				DE T2 69328975	09-11-2000
				DK T3 675886	18-09-2000
				EP A1 675886	11-10-1995
				EP A1 806423	12-11-1997
				EP B1 675886	05-07-2000
				ES T3 2147759	01-10-2000
				FI A0 935529	09-12-1993
				FI A 935529	11-06-1994
				GR T3 3034329	29-12-2000
				IL A0 107843	12-04-1994
				JP T2 7509490	19-10-1995
				JP B2 2722279	04-03-1998
				JP A2 10095780	14-04-1998
				MX A1 9307810	29-07-1994
				PT T 675886	29-12-2000
				US A 5854262	29-12-1998

This Page Blank (uspto)